Mithra secures court protection measures to advance monetization process
22. April 2024 01:00 ET
|
Mithra Pharmaceuticals
Court Grants "Transfer under Judicial Supervision" for CDMO facility, safeguarding Mithra's activities and expediting the M&A process for its Contract Development and Manufacturing...
Mithra reports full year 2023 financial results
08. März 2024 01:00 ET
|
Mithra Pharmaceuticals
Mithra reports full year 2023 financial results Revenues were EUR 40.2 million, down from the 2022 result of EUR 67.0 million which was positively impacted by exceptional upfront cash payments from...
Mithra announces changes to its executive management
05. März 2024 01:01 ET
|
Mithra Pharmaceuticals
Mithra announces changes to its executive management Liege, Belgium, 05 March 2024 – 07:00 CET – Mithra (Euronext Brussels: MITRA), a company dedicated to women’s health, today announces the...
Mithra initiates monetization process, receives bridge loan from existing lenders
05. März 2024 01:00 ET
|
Mithra Pharmaceuticals
Mithra initiates monetization process, receives bridge loan from existing lenders Mithra appoints advisors and initiates a process to monetize its assets or execute a sale of its businessMithra...
DONESTA® safety study for menopause completes treatment phase and advances to data management & reporting phase
29. Februar 2024 05:42 ET
|
Mithra Pharmaceuticals
DONESTA® safety study for menopause completes treatment phase and advances to data management & reporting phase Mithra on-track for completion of Phase 3 study for DONESTA® to treat...
Mithra sells shares in Mayne Pharma
15. Februar 2024 12:23 ET
|
Mithra Pharmaceuticals
Mithra sells shares in Mayne Pharma Mithra sold all 4,221,815 shares it held in Mayne Pharma for EUR ~12.8 millionAs the Mayne Pharma shares were pledged to the secured lenders of Mithra,...
Mithra and Rafa Laboratories sign binding Head of Terms to commercialize DONESTA® in Israel
21. Dezember 2023 11:45 ET
|
Mithra Pharmaceuticals
Mithra and Rafa Laboratories sign binding Head of Terms to commercialize DONESTA® in Israel Rafa Laboratories to receive the exclusive commercial rights for DONESTA® in Israel on the...
Mithra Completes Pediatric Study of ESTELLE® in Adolescent Patients
20. Dezember 2023 11:45 ET
|
Mithra Pharmaceuticals
Mithra Completes Pediatric Study of ESTELLE® in Adolescent Patients Important milestone for Mithra’s commitment to bring benefits of ESTELLE® to more womenPotential EMA approval in pediatric...
Mithra and Gedeon Richter sign binding Head of Terms to commercialize ESTELLE® and DONESTA® in China
04. Dezember 2023 01:00 ET
|
Mithra Pharmaceuticals
Mithra and Gedeon Richter sign binding Head of Terms to commercialize ESTELLE® and DONESTA® in China Mithra signs binding Head of Terms for a twenty-year partnership with Gedeon-Richter...
Mithra receives guidance from the FDA for the DONESTA® NDA marketing authorization filing in the United States
30. November 2023 01:00 ET
|
Mithra Pharmaceuticals
Mithra receives guidance from the FDA for the DONESTA® NDA marketing authorization filing in the United States DONESTA® for the treatment of vasomotor symptoms of menopause, is expected to target...